SCHEMBL696635

SCHEMBL696635

Cc1cc(Cl)ccc1S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31514000 1.00
SCHEMBL3133477 0.79
SCHEMBL8593167 0.77 ESR2 (0.62)
SCHEMBL8337554 0.75 CYP2A6 (0.46)
SCHEMBL8289896 0.75 CYP2A6 (0.46)
SCHEMBL330857 0.75
SCHEMBL29767277 0.75
SCHEMBL31556280 0.75
SCHEMBL91997 0.75
SCHEMBL29497656 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509462-B2 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5A]quinazolin-5(4H)-one derivatives BioVersys AG (CH) 2025-12-30 US disclosed
EP-3887375-B1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2024-11-20 EP disclosed
US-11945790-B2 Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2024-04-02 US disclosed
WO-2022140464-A1 COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
US-20220204471-A1 Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. 2022-06-30 US disclosed
US-20220204471-A1 Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. 2022-06-30 US disclosed
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2022-01-27 US disclosed
EP-3887375-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES Bioversys AG (CH) 2021-10-06 EP disclosed
CN-108102103-B Preparation method and application of micromolecular phosphate additive 江苏苏博特新材料股份有限公司 2020-12-29 CN disclosed
WO-2020109350-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2020-06-04 WO disclosed
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-07-08 US disclosed
WO-2004037176-A2 QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-06 WO disclosed
WO-2004031145-A2 LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-15 WO disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 EP disclosed
US-6333341-B1 TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS AMGEN INC. 2001-12-25 US disclosed
EP-0203827-B1 PROCESS FOR PREPARING ORTHO-(ALKYLTHIO) PHENOLS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-04-05 EP disclosed
EP-0203827-A1 Process for preparing ortho-(alkylthio) phenols E.I. DU PONT DE NEMOURS AND COMPANY (US) 1986-12-03 EP disclosed
US-4599451-A PHENOL WITH DIALKYL DISULFIDE, ZIRCONIUM PHENOXIDE CATALYST E. I. DUPONT DE NEMOURS AND COMPANY (US) 1986-07-08 US disclosed
US-4113939-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1978-09-12 US disclosed
US-4058392-A Tetrasubstituted urea compounds and herbicidal compositions BAYER AKTIENGESELLSCHAFT (DT) 1977-11-15 US disclosed